146
Participants
Start Date
May 1, 2024
Primary Completion Date
May 30, 2027
Study Completion Date
May 30, 2027
Nimotuzumab
Patients will receive Nimotuzumab 400 mg weekly or Nimotuzumab 600 mg on Day 1 and 8 of a 21-day cycle, up to 6 months.
GX
Patients will receive GX as adjuvant therapy for 6 months. Gemcitabine will be delivered as a 1000 mg/m² intravenous infusion administered on Day 1 and 8 of a 21-day cycle. Capecitabine 2000mg/m²/day will be administered orally for 14 days followed by 7 days' rest.
Placebo
Patients will receive placebo 400 mg weekly or placebo 600 mg on Day 1 and 8 of a 21-day cycle, up to 6 months.
Tianjin Medical University Cancer Institute and Hospital, Tianjin
Tianjin Medical University Cancer Institute and Hospital
OTHER